<DOC>
	<DOCNO>NCT01093040</DOCNO>
	<brief_summary>To assess safety administration drug ( CAT-354 ) healthy Japanese subject .</brief_summary>
	<brief_title>A Study Assess Safety Immunogenicity Drug CAT-354 Healthy Japanese Subjects</brief_title>
	<detailed_description>The study design allow gradual escalation dose safety monitoring ensure safety subject .</detailed_description>
	<criteria>Male female subject age 20 55 year time screen Signed dated write informed consent obtain prior study related procedure take place No significant abnormality clinical examination medical history ( exclude atopic skin sign , symptom history ) A normal 12lead electrocardiogram ( ECG ) ( clinically significant abnormality ) Clinical chemistry , hematology urinalysis result within laboratory reference range deem clinically significant Investigator A negative screen drug abuse alcohol The following reproductive criterion apply : Females ( child bear potential ) must negative pregnancy test prior dose investigational product , unless surgically sterile ( ie , bilateral tubal ligation , bilateral oophorectomy , complete hysterectomy ) , sterile male partner , least 2 year postmenopausal , practice abstinence ; must use 2 effective method avoid pregnancy ( include oral , transdermal , implanted hormonal contraceptive , intrauterine device , female condom spermicide , diaphragm spermicide , cervical cap spermicide , use condom spermicide sexual partner ) 21 day prior randomization , must agree continue use precaution 3 month dose investigational product ; cessation birth control point discuss responsible physician . A negative pregnancy test require screen prior dosing . Males , unless surgically sterile , must use two effective method birth control female partner must agree continue use contraceptive precaution 21 day prior randomization 3 month dose investigational product . Japanese subject . To consider 'Japanese ' , subject 's parent , set grandparent , must Japanese . The subject must bear Japan , valid Japanese passport , must live outside Japan 5 year . Body mass index ( BMI ) 18 27 kg/m 2 , inclusive Able comply requirement protocol Any condition , opinion investigator , would interfere evaluation investigational product interpretation subject safety study result Previously receive monoclonal antibody , similar relate protein , might sensitize subject CAT354 component investigational product formulation History active infection within 4 week prior screen , evidence clinically significant active infection , include ongoing chronic infection Any acute illness 14 day Day 1 ( Visit 2 ) Use medication ( prescription OTC ) exclude hormonal contraception within 14 day ( 5half life , whichever long ) Day 1 dose Involvement another study investigational medicinal product ; within 2 month start study ( Day 1 ) small molecule , within 3 month start study antibody , 5 half live previously administer investigational product , whichever longer Any blood donation significant loss blood within 56 day study initiation plasma donation within 7 day study initiation Subjects immunodeficiency disorder Subjects positive test , treat hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) Any active concomitant disease include psychological disorder Subject participate Investigator , subInvestigator , study coordinator , employee participate Investigator , firstdegree relative aforementioned . Any factor , opinion Investigator , would associate poor adherence protocol Female subject : lactation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>